Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
20.82
-0.44 (-2.07%)
Apr 29, 2026, 1:34 PM EDT - Market open
Summit Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 16,158 | 13,487 | 13,160 | 1,829 | 897 | 263 | |
| Market Cap Growth | -5.75% | 2.49% | 619.43% | 103.94% | 241.23% | -32.01% | |
| Enterprise Value | 15,807 | 13,254 | 12,705 | 1,737 | 779 | 184 | |
| Last Close Price | 21.26 | 17.49 | 17.84 | 2.61 | 4.25 | 2.69 | |
| PS Ratio | - | - | - | - | 1272.24 | 145.30 | |
| PB Ratio | 25.02 | 20.47 | 33.85 | 23.54 | 7.08 | 3.16 | |
| P/TBV Ratio | 25.12 | 20.53 | 34.02 | 24.13 | 7.18 | 3.71 | |
| EV/Sales Ratio | - | - | - | - | 1105.42 | 101.96 | |
| Debt / Equity Ratio | 0.03 | 0.03 | 0.02 | 1.37 | 4.10 | 0.03 | |
| Net Debt / Equity Ratio | -1.05 | -1.05 | -1.04 | -1.03 | 1.34 | -0.83 | |
| Net Debt / EBITDA Ratio | 0.63 | 0.63 | 1.92 | 0.91 | -2.73 | 0.81 | |
| Net Debt / FCF Ratio | 2.14 | 2.14 | 2.85 | 1.04 | -4.03 | 0.95 | |
| Asset Turnover | - | - | - | - | 0.00 | 0.02 | |
| Quick Ratio | 9.78 | 9.78 | 9.88 | 9.17 | 9.15 | 3.47 | |
| Current Ratio | 9.87 | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | |
| Return on Equity (ROE) | -206.10% | -206.10% | -94.89% | -601.85% | -75.05% | -108.89% | |
| Return on Assets (ROA) | -115.28% | -115.28% | -41.30% | -12.79% | -10.23% | -49.91% | |
| Return on Capital Employed (ROCE) | -161.40% | -161.40% | -53.60% | -48.60% | -10.20% | -98.20% | |
| Earnings Yield | -6.54% | -8.00% | -1.68% | -33.62% | -8.78% | -33.71% | |
| FCF Yield | -1.96% | -2.40% | -1.08% | -4.20% | -4.71% | -27.73% | |
| Buyback Yield / Dilution | -4.06% | -4.06% | -15.96% | -220.50% | -109.60% | -32.67% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.